A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid

Pancreatic adenocarcinoma is a common disease considered to be poorly responsive to antiblastic treatment. Recent clinical and preclinical results suggest that a combined treatment of gemcitabine (GEM), 5-flurouracil (5-FU) and folinic acid (FA) offers a clinical benefit in patients with advanced pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Correale, P, Messinese, S, Marsili, S, Ceciarini, F, Pozzessere, D, Petrioli, R, Sabatino, M, Cerretani, D, Pellegrini, M, Di Palma, T, Neri, A, Calvanese, A, Pinto, E, Giorgi, G, Francini, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394244/
https://www.ncbi.nlm.nih.gov/pubmed/12865908
http://dx.doi.org/10.1038/sj.bjc.6601045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394244/
https://www.ncbi.nlm.nih.gov/pubmed/12865908
http://dx.doi.org/10.1038/sj.bjc.6601045

Ejemplares similares